Leah Lawrence

Selinexor combined with ruxolitinib improves spleen response in myelofibrosis patients, offering a new treatment avenue.

'Most of the time we undertreat,' says expert

The treatment landscape for these patients is evolving

Learn how tafasitamab with lenalidomide and R-CHOP enhances survival in high-risk diffuse large B-cell lymphoma in the phase 3 frontMIND trial.

Teclistamab improves response rates and progression-free survival in high-risk smoldering multiple myeloma, per phase 2 trial data.

Talquetamab-containing regimens significantly improve progression-free survival in patients with relapsed or refractory multiple myeloma, according to the MonumenTAL-3 trial.

July 2026 Combining the oral menin inhibitor ziftomenib with standard 7+3 induction chemotherapy yielded deep and durable responses in

July 2026 Older patients with advanced-stage classic Hodgkin lymphoma (AS-cHL) achieved long-term disease control with lower rates of relapse

ADCs have moved from the salvage setting into first-line treatment

Leah Lawrence Antibody-drug conjugates (ADCs) are becoming an increasingly relevant first-line treatment option for metastatic triple-negative breast cancer (TNBC).